Transepithelial topography-guided photorefractive keratectomy in corneal scar treatment: 12 months unicentral study

Session Details

Session Title: Advanced Surface Photoablation I

Session Date/Time: Sunday 08/10/2017 | 08:00-09:30

Paper Time: 08:45

Venue: Meeting Center Room I

First Author: : R.Makarov RUSSIA

Co Author(s): :    I. Mushkova   N. Maychuk                 

Abstract Details

Purpose:

To demonstrate the efficacy, predictability and safety of Transepithelial Topography-guided Photorefractive Keratectomy (TT-PRK) in stromal corneal scars treatment.

Setting:

The S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia

Methods:

Twenty eyes of 19 patients with postinfectious (n=14), post-traumatic (n=2), and post-PRK (n=4) scars were evaluated with manifest spectacle refraction, best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA), corneal density, and topographic indexes of surface regularity (SAI - Surface Asymmetry Index and SRI - Surface Regularity Index) before and up to 12 months after TT-PRK performed with excimer laser MicroScan-Visum and KeraScan software (OptoSystems, Russia)

Results:

The mean SAI and SRI significantly improved from 2.07±1.4 to 0.9±0.53 and from 1.35±0.55 to 0.51±0.22, respectively (P< .001). The mean corneal density in anterior and central layers changed from 38.44±5.15 to 30.09±5.4 and from 20.59±3.49 to 17.2±2.95, respectively (P< .001). The mean value of UCDVA improved significantly (P < .001) from 0.78±0.25 logMAR to 0.23±0.09 logMAR, and the BSCVA improved from 0.36±0.19 logMAR to 0.1±0.07 logMAR (P< .001). The mean spherical equivalent refraction changed from -3.93±3.22 D to -0.73±0.92 D (P< .001)

Conclusions:

The using of TT-PRK with Russian made excimer laser and software in stromal corneal opacities treatment resulted in significant increasing of UCVA and BSCVA as well as corneal transparency improving in all patients. The technique seems to be safe and effective for treating various stromal corneal scars, including postinfectious, post-traumatic, and post-PRK opacities

Financial Disclosure:

NONE